Document Detail

Nonoperable patients with superficial esophageal cancer treated by photodynamic therapy after chemoradiotherapy have more severe complications than patients treated in primary intent.
MedLine Citation:
PMID:  18844614     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Photodynamic therapy (PDT) is a therapeutic option in patients with a superficial esophageal cancer. Recently, PDT was shown to be effective as a salvage therapy for a local recurrence after chemoradiotherapy (CRT). AIM: To compare retrospectively the results and the complications rate of PDT between consecutive patients treated in primary intent for a superficial esophageal cancer versus patients treated by PDT for a local recurrence after CRT. METHODS: Between 1999 and 2007 in a single center, 40 consecutive patients were treated by PDT for a superficial esophageal cancer, 25 (group 1) in primary intent and 15 (group 2) for a local recurrence after CRT. Two days after intravenous (IV) Photofrin (2 mg/kg), the phototherapy was performed with a dye laser. The treatment response and severe complications, defined as perforation and stricture requiring endoscopic dilation, were compared between the two groups. RESULTS: The patient and tumor characteristics were not different between the two groups. In group 1, 19 out of 25 patients (76%) were successfully treated versus 8 out of 15 patients (53%) in group 2 (P= 0.17). Severe complications occurred more frequently in patients with a prior CRT (8%vs 46.7%, P= 0.008) and included two perforations and five strictures requiring endoscopic dilation, while only two strictures occurred in group 1. A prior CRT was an independent risk factor of severe complications (odds ratio [OR] 8.05; 95% confidence interval [CI]1.22-43.0). CONCLUSIONS: Severe complications were significantly more frequent in patients treated after a prior CRT. PDT as a salvage therapy in patients with a local recurrence after CRT for esophageal cancer tended to be less efficient than in first-line treatment.
Stéphane Lecleire; Frédéric Di Fiore; Michel Antonietti; Emmanuel Ben-Soussan; Patrick Hochain; Eric Lerebours; Pierre Michel; Philippe Ducrotté
Related Documents :
3566374 - Esophagogastrectomy for benign esophageal stricture. fate of the esophagogastric anasto...
15571574 - Long-term follow-up after pneumatic dilation for achalasia cardia: factors associated w...
18197944 - Influence of esophageal motility on the outcome of laparoscopic total fundoplication.
12928084 - Histologic features of reflux-attributed laryngeal lesions.
3184304 - The daytime urinary frequency syndrome of childhood.
20508304 - Histo-morpho-biochemical findings of the residual prostate (iii): (undetectable) psa ma...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  103     ISSN:  1572-0241     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-10-10     Completed Date:  2008-12-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2215-9     Citation Subset:  IM    
Department of Hepato-Gastroenterology and Nutrition and Appareil Digestif et Nutrition Equipe d'Accueil 3234, Rouen University Hospital, Rouen, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chi-Square Distribution
Combined Modality Therapy
Dihematoporphyrin Ether / adverse effects,  therapeutic use
Esophageal Neoplasms / drug therapy,  pathology,  radiotherapy,  therapy*
Logistic Models
Neoplasm Staging
Photochemotherapy / adverse effects*
Photosensitizing Agents / adverse effects,  therapeutic use
Retrospective Studies
Risk Factors
Salvage Therapy
Statistics, Nonparametric
Treatment Outcome
Reg. No./Substance:
0/Photosensitizing Agents; 97067-70-4/Dihematoporphyrin Ether

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expres...
Next Document:  HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carrier...